FDA doubles down on rejecting over-the-counter CBD without more study
Federal food and drug regulators on Tuesday addressed the hemp industry directly for the first time since stakeholders asked for feedback regarding CBD safety back in 2019. But the message was a familiar one. Grail Sipes, acting cannabis-product committee chair with the U.S. Food and Drug Administration, reiterated the agency’s position that it needs additional CBD research and safety data before it can be considered for uses beyond prescription drugs, such as a food additive or dietary supplement.
